U.S., Feb. 6 -- ClinicalTrials.gov registry received information related to the study (NCT07388277) titled 'CC-97540 in Patients With Antineutrophil Cytoplasmic Antibody-associated Vasculitis' on Jan. 28.
Brief Summary: The purpose of this study is to evaluate the safety of CC-97540 in relapsed or refractory severe antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis.
Study Start Date: July 09, 2026
Study Type: INTERVENTIONAL
Condition:
Antineutrophil Cytoplasmic Antibody-associated Vasculitis
Intervention:
DRUG: CC-97540
Intravenous infusion
DRUG: Lymphodepletion Chemotherapy
Intravenous infusion of cyclophosphamide and fludarabine
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Marcela V. Maus, M.D.,Ph.D.
Informat...